However, there are still patients without FLT3-ITD/NPM1 or CEBPA double mutations in which additional prognostic biomarkers would be of high value to further assess the prognosis of the intermediate risk NK-AML patient group. The gene discussed is NPM1; the disease is acute myeloid leukemia.